AbbVie's moderate-severe psoriasis treatment Skyrizi PFS has agreed to a PVA negotiation, which is expected to reduce the upper limit. The drug was registered in June 2020, and it is analyzed that it exceeded the expected claim agreed in advance with the NHIS from 2021. According to the industry on the 3rd, the NHIS has completed PVA negotiations with AbbVie which will be reflected in the list as of March 1. Skyrizi was also a PVA-monitoring drug in the third quarter of last year. As type A, this is the first upper limit under PVA negotiations.

In patients with moderate to severe psoriasis lasting more than 6 months, if ▲Plaque psoriasis is more than 10% of the total skin area, ▲PASI 10 or higher, ▲